South San Francisco, California

White Biotechnology Market Overview 2018 Key Players Analysis Novozymes, Global Bioenergies, Amyris, Gevo, BioAmber, Deinove

Retrieved on: 
Monday, September 17, 2018
South San Francisco, California, TerraVia, Gevo, Inc, Biotechnology, Codexis, SWOT analysis, Economy, California

ReportsnReports published report Global White Biotechnology Market status and forecast, categorizes the global White Biotechnology Industry size (value & volume) by manufacturers, type, application, and region.

Key Points: 
  • ReportsnReports published report Global White Biotechnology Market status and forecast, categorizes the global White Biotechnology Industry size (value & volume) by manufacturers, type, application, and region.
  • Organizations profiled in this White Biotechnology market statistical surveying incorporate are Novozymes, Global Bioenergies, Metabolic Explorer, Amyris, Gevo, BioAmber, Deinove, Solazyme, Evolva, Fermentalg, Borregaard and Codexis.
  • The study objectives of this report are:
    To study and forecast the market size of White Biotechnology in global market.
  • To analyze the global key players, SWOT analysis, value and global market share for top players.

Sutro Taps Worsley as Chief Business Officer; Names Fitzpatrick as People and Communications Chief

Retrieved on: 
Wednesday, September 12, 2018
South San Francisco, California, Sutro Biopharma, Sutro

SOUTH SAN FRANCISCO, Sept. 12, 2018 /PRNewswire/ -- Sutro Biopharma, Inc. , has appointed Stephen Worsley as chief business officer and has named Linda Fitzpatrick to the newly-created post of chief people and communications officer.

Key Points: 
  • SOUTH SAN FRANCISCO, Sept. 12, 2018 /PRNewswire/ -- Sutro Biopharma, Inc. , has appointed Stephen Worsley as chief business officer and has named Linda Fitzpatrick to the newly-created post of chief people and communications officer.
  • Mr. Worsley has over 25 years of biotechnology experience and will oversee business development and corporate strategy.
  • As the pace of clinical development accelerates, Sutro and its partners are developing therapeutics designed to more efficiently kill tumors without harming healthy cells.
  • Follow Sutro on Twitter, @Sutrobio, and at www.sutrobio.com to learn more about our passion for changing the future of oncology.

Sutro Biopharma Collaborates with Merck to Develop Therapeutics for Cancer and Autoimmune Disorders

Retrieved on: 
Tuesday, July 24, 2018
South San Francisco, California, Sutro Biopharma, Pharmacology, Biotechnology, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., July 24, 2018 /PRNewswire/ -- Sutro Biopharma, Inc., has signed a collaboration and licensing agreement with Merck, known as MSD outside the United States and Canada, to discover and develop novel immune-modulating therapies for cancer and autoimmune disorders.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., July 24, 2018 /PRNewswire/ -- Sutro Biopharma, Inc., has signed a collaboration and licensing agreement with Merck, known as MSD outside the United States and Canada, to discover and develop novel immune-modulating therapies for cancer and autoimmune disorders.
  • Under the agreement, Sutro will be primarily responsible for preclinical research and Merck will gain exclusive worldwide rights to therapeutic candidates derived from the collaboration.
  • "There's an urgent need for novel, targeted and well-tolerated therapies with improved therapeutic profiles for cancer and autoimmune disease," Sutro CEO Bill Newell said.
  • We look forward to collaborating with Sutro to further expand our pipeline of promising candidates targeting oncology and autoimmune diseases."

Second Genome Appoints Anupama S. Hoey as Chief Business Officer

Retrieved on: 
Monday, July 23, 2018
South San Francisco, California, Sutro Biopharma

SOUTH SAN FRANCISCO, Calif., July 23, 2018 /PRNewswire/ --Second Genome, Inc., a leader in the development of novel therapeutics derived from the human microbiome, today announced the appointment of Anupama S. Hoey as chief business officer.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., July 23, 2018 /PRNewswire/ --Second Genome, Inc., a leader in the development of novel therapeutics derived from the human microbiome, today announced the appointment of Anupama S. Hoey as chief business officer.
  • In her role, Ms. Hoey will be leading all corporate development activities and strategic alliance opportunities for the company.
  • Prior to joining Second Genome, Ms. Hoey served as the chief business officer at Invenra, Inc., where she successfully executed multiple high-profile deals with pharmaceutical companies and leading academic institutions.
  • Before that, she served as vice president of business development at Arcus Biosciences, and as senior director of business development at Sutro Biopharma.

FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin

Retrieved on: 
Wednesday, July 11, 2018
Biotechnology, Health, Biology, Specialty drugs, Immunology, Genentech, Hoffmann-La Roche, South San Francisco, California, Trastuzumab, Biopharmaceutical, Trastuzumab emtansine, Antibody-drug conjugate

SAN DIEGO, July 11, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application from Genentech, a member of the Roche Group, for a subcutaneous (SC) formulation of trastuzumab (Herceptin) in its FDA-approved breast cancer indications.

Key Points: 
  • SAN DIEGO, July 11, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application from Genentech, a member of the Roche Group, for a subcutaneous (SC) formulation of trastuzumab (Herceptin) in its FDA-approved breast cancer indications.
  • "If approved, this formulation would provide a new treatment administration option for patients and health care practitioners."
  • Roche reported total 2017 sales of Herceptin in the United States of 2.7 billion CHF.
  • Herceptin (trastuzumab) is a registered trademark of Genentech, a member of the Roche Group.

goBalto Spearheads Benchmarking and Analytic Data Initiatives in Starting Clinical Trials

Retrieved on: 
Monday, June 25, 2018
Health, Clinical research, Pharmaceutical industry, Drug discovery, Genentech, Hoffmann-La Roche, South San Francisco, California, Benchmarking, Clinical trial

SAN FRANCISCO, June 25, 2018 /PRNewswire/ --goBalto, Inc., the leading provider of cloud-based clinical study startup solutions, announced today its latest version of goBalto Analyze.

Key Points: 
  • SAN FRANCISCO, June 25, 2018 /PRNewswire/ --goBalto, Inc., the leading provider of cloud-based clinical study startup solutions, announced today its latest version of goBalto Analyze.
  • The sharpening focus on quality management and efficiencies is fueling greater use of standardized metrics to optimize clinical trial performance.
  • goBalto also announces the industry's first, real-time benchmarking visualizations of study startup performance based on therapeutic areas and country.
  • Our customers include: Allergan, Covance, CMIC HOLDINGS, Genentech Roche, ICON, Novartis, PSI CRO, Syneos Health, TFS International, and Worldwide Clinical Trials.

Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2018 On May 9, 2018

Retrieved on: 
Monday, April 30, 2018
Chemistry, Organic chemistry, Clinical medicine, MEK inhibitor, Protein kinase inhibitors, Alcohols, Chloroarenes, South San Francisco, California, Binimetinib, Array BioPharma, Tucatinib, Larotrectinib

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other conditions.

Key Points: 
  • Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other conditions.
  • Ten registration studies are currently advancing related to eight Array-owned or partnered drugs: encorafenib (LGX818), binimetinib (MEK162), ARRY-797, selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Seattle Genetics).
  • For more information on Array, please go to www.arraybiopharma.com .